T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) drugs

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) overview

T-cell acute lymphoblastic leukemia (T-ALL) is a type of blood cancer that affects T-cell lymphocytes, a type of white blood cell involved in the immune system’s function. T-ALL originates from immature T-cells in the bone marrow that fail to mature into normal functioning T-cells. These abnormal cells grow rapidly, crowding out normal blood cells (red blood cells, white blood cells, and platelets) in the bone marrow. T-ALL is more prevalent in children and adolescents than in adults. It accounts for approximately 15% of pediatric acute lymphoblastic leukemia (ALL) cases. The exact cause of T-ALL is not fully understood. However, certain risk factors have been identified, including genetic factors, exposure to high levels of radiation or certain chemicals, and certain genetic disorders or inherited syndromes.

For a complete picture of PTSR and LoA scores for drugs in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.